Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 versus 6 cycles of platinum-based chemotherapy before maintenance avelumab in advanced urothelial cancer
2021-001975-17Phase 2Active
- Sponsor
- Queen Mary University of London
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avelumab, cisplatin, gemcitabine and carboplatin in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Queen Mary University of London. Started Nov 2021; status: active.
02
Drugs
avelumabcisplatingemcitabinecarboplatin
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2021-001975-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001975-17.